FREDUN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 839.6 INR | -0.89% |
|
-4.63% | -3.35% |
| May. 10 | Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24 | CI |
| May. 08 | Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9% | MT |
| Sales 2022 | 2.24B 27.03M | Sales 2023 | 2.75B 33.08M | Capitalization | 3.57B 43.01M |
|---|---|---|---|---|---|
| Net income 2022 | 63M 759K | Net income 2023 | 108M 1.3M | EV / Sales 2022 | 2.07 x |
| Net Debt 2022 | 586M 7.05M | Net Debt 2023 | 831M 10.01M | EV / Sales 2023 | 1.6 x |
| P/E ratio 2022 |
64.1
x | P/E ratio 2023 |
32.2
x | Employees | 260 |
| Yield 2022 |
0.08% | Yield 2023 |
0.09% | Free-Float | 41.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.89% | ||
| 1 week | -4.63% | ||
| Current month | -10.26% | ||
| 1 month | -0.56% | ||
| 3 months | -3.78% | ||
| 6 months | -4.37% | ||
| Current year | -3.35% |
1 week
830.40
890.00
1 month
802.001 024.00
Current year
650.001 054.00
1 year
650.001 249.00
3 years
351.201 428.00
5 years
103.001 428.00
10 years
12.501 428.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 37 | 06-09-14 | |
| Chief Executive Officer | 79 | 87-06-07 | |
Jinkal Shah
CMP | Compliance Officer | - | 22-01-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 79 | 87-06-07 | |
| Director/Board Member | 54 | 15-05-29 | |
| Director/Board Member | 75 | 15-09-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 839.6 | -0.89% | 1,108 |
| 24-05-23 | 847.2 | +0.12% | 9,958 |
| 24-05-22 | 846.2 | +0.37% | 3,299 |
| 24-05-21 | 843 | -4.25% | 7,399 |
| 24-05-18 | 880.4 | +1.16% | 1,304 |
Delayed Quote Bombay S.E., May 24, 2024 at 06:00 am EDT
More quotes
Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is primarily engaged in the business of pharmaceuticals and healthcare. The Company operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.35% | 47.5M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- FREDUN6 Stock
